Can MS Be Stopped Early in its Tracks? : vimarsana.com

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.

Related Keywords

California , United States , Santa Monica , Dallas , Texas , University Of Texas Southwestern Medical Center , Amsterdam , Noord Holland , Netherlands , Celgene Bristol Myers Squibb , Viela Bio , Barbara Giesser , Darin Okuda , Serono Merck , Genentech , Pacific Neuroscience Institute In Santa Monica , Novartis , Janssen Pharmaceuticals , Osmotica Pharmaceuticals , Serono , Research In Multiple Sclerosis , European Committee For Treatment , Texas Southwestern Medical Center , European Committee , Multiple Sclerosis , Medscape Medical News , Pacific Neuroscience Institute , Bristol Myers Squibb , Multiple Sclerosis Ms , Us , Ms Lesion , Ultiple Sclerosis Lesion , Multiple Sclerosis Imaging , S Imaging , Maging In Multiple Sclerosis , Maging In Ms , Maging Studies In Multiple Sclerosis , Maging Studies In Ms , Multiple Sclerosis Progression , Als Progression , Multiple Sclerosis Treatment , Als Treatment , Reatment Of Multiple Sclerosis , Reatment Of Ms , Disease Modifying Therapy , ,